{
    "data": [
        {
            "title": "Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nClarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">LONDON, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Software-as-a-Service, cloud-based library services and discovery platform to be implemented in nine universities and 82 academic and research libraries across <span data-v-370fea16=\"\">Croatia</span></em></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">LONDON</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=4011963572&amp;u=https%3A%2F%2Fclarivate.com%2F&amp;a=Clarivate+Plc\" tabindex=\"0\">Clarivate Plc</a> (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that the National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span> has selected Clarivate to provide its unified library services and discovery platform.</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg\"/></source></source></source></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span> (NSK) is <span data-v-02ca9be7=\"\">Croatia's</span> leading cultural and research institution, serving as both the National Library of <span data-v-02ca9be7=\"\">Croatia</span> and the University of <span data-v-02ca9be7=\"\">Zagreb's</span> main library. Its mission is to develop collections and services that promote <span data-v-02ca9be7=\"\">Croatia's</span> cultural and scientific heritage as well as to build a Croatian national library system.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The NSK will implement <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3006744924&amp;u=https%3A%2F%2Fexlibrisgroup.com%2Fproducts%2Falma-library-services-platform%2F%3Fcampaignname%3DPR_LeadGen_AG_XBU_Global%26campaignid%3D701QO00000QviLVYAZ%26utm_campaign%3DPR_LeadGen_AG_XBU_Global%26utm_source%3DPress_Release%26utm_medium%3DEarned_Press%26utm_content%3D%26utm_term%3D&amp;a=Ex+Libris+Alma\" tabindex=\"0\">Ex Libris Alma</a> and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3723195327&amp;u=https%3A%2F%2Fexlibrisgroup.com%2Fproducts%2Fprimo-discovery-service%2F%3Fcampaignname%3DPR_LeadGen_AG_XBU_Global%26campaignid%3D701QO00000QviLVYAZ%26utm_campaign%3DPR_LeadGen_AG_XBU_Global%26utm_source%3DPress_Release%26utm_medium%3DEarned_Press%26utm_content%3D%26utm_term%3D&amp;a=Ex+Libris+Primo\" tabindex=\"0\">Ex Libris Primo</a> from Clarivate to build a modern, unified library system, streamlining the existing infrastructure of multiple library systems and data formats. The NSK will lead the new solution for the academic and research library system across the country, totaling nine universities and 82 libraries, with a cloud-based subscription service.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Professor Stričević, Director General, NSK said: \"I am pleased that the National and University Library selected Alma and Primo as a unified solution that will foster the process of digital transformation of the university library system in <span data-v-02ca9be7=\"\">Croatia</span> with the National and University Library at the forefront. The activity is realized as part of the<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3750775116&amp;u=https%3A%2F%2Fwww.carnet.hr%2Fen%2Fprojekt%2Fe-universities%2F&amp;a=+e-Universities+project\" tabindex=\"0\"> e-Universities project</a> and financed from the National Recovery and Resilience Plan 2021 – 2026.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Dr <span data-v-02ca9be7=\"\">Dijana Machala</span>, Assistant Director, University Library Affairs, NSK, who is leading this national strategic project said: \"We are excited to start the implementation of Alma Network Zone for NSK and 82 academic and research libraries in <span data-v-02ca9be7=\"\">Croatia</span>. NSK selected Alma and Primo with the aim to provide a resilient library digital infrastructure that will empower learning and research.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Yariv Kursh</span>, Senior Vice President and General Manager, Ex Libris and Innovative, part of Clarivate said: \"At Clarivate, we are dedicated to providing forward thinking solutions that support the missions of national libraries such as the National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span>. Today's announcement is yet another example of our national-level collaboration with libraries and is testament to how we support and empower them through transformational change. Our collaboration will foster learning and discovery for future generations and make <span data-v-02ca9be7=\"\">Croatia's</span> rich heritage accessible to researchers, scholars and the public.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Clarivate</strong><br data-v-02ca9be7=\"\"/>Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights &amp; analytics, workflow solutions and expert services in the areas of Academia &amp; Government, Intellectual Property and Life Sciences &amp; Healthcare. For more information, please visit www.clarivate.com</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content to download multimedia:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform-302367687.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform-302367687.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Clarivate Plc</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:15:46",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny11283/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nAfrica’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, organized by Africa CDC and hosted by the Egyptian United Procurement Authority (UPA) in Cairo. This collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThe platform, taking place in Egypt, will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify<span data-v-02ca9be7=\"\">®</span> mRNA synthesis and Ncapsulate<span data-v-02ca9be7=\"\">®</span> formulation technologies, combined with EVA Pharma’s vaccine development, top notch GMP sterile manufacturing expertise and commercialization capabilities. The collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing next generation saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases at their source.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThis initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030, establishing itself as a global leader in vaccine production. It also supports public health resilience and food security across Africa and the Middle East.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n“This moment will reshape African and global health security as we know it,” said Dr. Riad Armanious, CEO of EVA Pharma, expressing his enthusiasm. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nAccording to Marc Montserrat, CEO of DNA Script,\n<br data-v-02ca9be7=\"\"/>“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nJosé Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nHala Audi, CEO of Unizima, echoed this sentiment: “EVA Pharma is already showing the world the power of investing in the biopharma sector to create health and wealth in Africa and the Middle East. We are proud to support the tech transfer of some of the best technology for DNA and RNA manufacturing to Egypt, as the next chapter in their growth.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThis MoU reflects a strong commitment to advance global health equity and foster sustainable biopharma development. By combining their strengths, the partners aim to deliver versatile, scalable, and impactful solutions. These will shape the future of healthcare in Egypt and beyond, while contributing to economic resilience and regional pandemic preparedness and response.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About EVA Pharma</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nWith a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nGuided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nFor more information, please visit: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evapharma.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.evapharma.com&amp;index=1&amp;md5=4ccca5070f64fbdb80c1824ab69c3198\" tabindex=\"0\">www.evapharma.com</a> &amp; <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evapharma.com%2Fnewsroom&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.evapharma.com%2Fnewsroom&amp;index=2&amp;md5=38b2d3ad65988ac7f4ab0768ff8b986e\" tabindex=\"0\">https://www.evapharma.com/newsroom</a> or follow us on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FEvapharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b86c806045f1d5aac14daa6a02e2cc06\" tabindex=\"0\">Facebook</a>, <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Feva-pharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=a265adc842d0e2e0e8e084110d25569b\" tabindex=\"0\">LinkedIn</a> &amp; <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Feva.pharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=85de8f0ad98613fa5c359bc4c43067ec\" tabindex=\"0\">Instagram</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About EVA Pharma’s mRNA Innovation Hub</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma has notably focused on localizing innovation in recent years through investing in research infrastructure and financing. The company has established an in-house research and development footprint, including its mRNA Innovation Hub, which is fully equipped to handle the complete mRNA vaccine development lifecycle—from digital sequencing to final drug formulation. This includes antigen selection, protein engineering, mRNA construct design, process development, innovative formulation delivery systems, and analytical method development.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About DNA Script</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nDNA Script is at the forefront of transforming biological research through advanced enzymatic DNA synthesis technology. We provide pioneering solutions for DNA production, including our cutting-edge SYNTAX<span data-v-02ca9be7=\"\">®</span> DNA printer and our enzymatic synthesis technology that enables the production of longer and more complex DNA sequences. Our innovations are driving progress across critical scientific domains, including mRNA vaccine development, cell and gene therapy, and broader biomolecular research. By offering researchers unprecedented capabilities to synthesize high-quality DNA sequences, we are accelerating discoveries that have the potential to revolutionize healthcare, biotechnology, and scientific understanding. More info: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dnascript.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.dnascript.com&amp;index=6&amp;md5=6c084f6b9bcfb4c0b40a49b3bc0c0719\" tabindex=\"0\">www.dnascript.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Quantoom Biosciences</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nQuantoom Biosciences is leading the revolution in mRNA- and saRNA-based vaccines and therapeutics by providing turnkey solutions for (sa)mRNA &amp; LNP manufacturing. Its cutting-edge Ntensify<span data-v-02ca9be7=\"\">®</span> technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&amp;D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate<span data-v-02ca9be7=\"\">®</span> technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere. More info : <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quantoom.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.quantoom.com&amp;index=7&amp;md5=4dad06f6fa8e331fad48dad8982a3d29\" tabindex=\"0\">www.quantoom.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Unizima</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nUnizima is a trusted consultancy specialized in public and private partnerships for establishing bioproduction facilities and develop the workforce in emerging biotech ecosystems. As a partner to biopharma manufacturers, governments, and global health agencies, Unizima enables the sustainable production of biologics—including vaccines, monoclonal antibodies, and recombinant protein. From project inception to technology transfer and training, Unizima integrates all necessary elements to bring biomanufacturing initiatives to life. More info: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.unizima.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.unizima.com&amp;index=8&amp;md5=e04881b9c5dbabcc523afc3a2652d46a\" tabindex=\"0\">www.unizima.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Disclosure Statement</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThe contents of this announcement include statements that are, or may be deemed to be, \"forward-looking statements\". These forward-looking statements can be identified using forward-looking terminology, including the words \"believes\", \"estimates,\" \"anticipates\", \"expects\", \"intends\", \"may\", \"will\", \"plans\", \"continue\", \"ongoing\", \"potential\", \"predict\", \"project\", \"target\", \"seek\" or \"should\", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en\"/></source></source></source></picture></span><span data-v-02ca9be7=\"\"></span></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">EVA Pharma \n</strong><br data-v-02ca9be7=\"\"/>Marina Mansour\n<br data-v-02ca9be7=\"\"/>Corporate communications Professional\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:Marina.mansour@evapharma.com\" tabindex=\"0\">Marina.mansour@evapharma.com</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">DNA Script \n</strong><br data-v-02ca9be7=\"\"/>Rachel Macmaster, PhD\n<br data-v-02ca9be7=\"\"/>Director, Global Marketing\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:publicrelations@dnascript.co\" tabindex=\"0\">publicrelations@dnascript.co</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Quantoom Biosciences / Unizima \n</strong><br data-v-02ca9be7=\"\"/>Jonathan Lecocq\n<br data-v-02ca9be7=\"\"/>MarCom Manager\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:j.lecocq@quantoom.com\" tabindex=\"0\">j.lecocq@quantoom.com \n</a><br data-v-02ca9be7=\"\"/>+32 476 81 12 44\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">View source version on businesswire.com: </span><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.businesswire.com/news/home/20250205825293/en/\" tabindex=\"0\">https://www.businesswire.com/news/home/20250205825293/en/</a></span></p></div>",
            "pub_date": "2025-02-05 16:15:45",
            "link": "https://www.morningstar.com/news/business-wire/20250205825293/africa-and-europe-join-forces-to-revolutionize-rna-based-vaccines-and-therapeutics-production-mou-signed-between-eva-pharma-dna-script-quantoom-biosciences",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Ericsson appoints Charlotte Levert as Chief People Officer",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nEricsson appoints Charlotte Levert as Chief People Officer\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Ericsson appoints Charlotte Levert as Chief People Officer</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Effective as of <span data-v-6f730619=\"\">February 10, 2025</span></li><li data-v-6f730619=\"\">Becomes member of Ericsson's Executive Team, reporting to the CEO</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- Ericsson (NASDAQ: ERIC) today announces the appointment of <span data-v-02ca9be7=\"\">Charlotte Levert</span> as its new Chief People Officer, Senior Vice President, and Head of Group Function People. <span data-v-02ca9be7=\"\">Charlotte Levert</span> who is currently Vice President and Head of People Business Area Cloud and Software Services will replace <span data-v-02ca9be7=\"\">MajBritt Arfert</span>, whose departure Ericsson announced in <span data-v-02ca9be7=\"\">October 2024</span>. <span data-v-02ca9be7=\"\">Charlotte Levert</span> will take up her new position on <span data-v-02ca9be7=\"\">February 10</span> and will be based in <span data-v-02ca9be7=\"\">Sweden</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Charlotte Levert</span> has held executive positions within Ericsson across several business areas. She has most recently held the position of Head of People Business Area Managed Services. Before joining Ericsson, <span data-v-02ca9be7=\"\">Charlotte Levert</span> was Head of HR Sweden &amp; Global HR business partner at Tieto and has held various senior management positions within human resources. She holds a Bachelor in Business Management &amp; Human Resources.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Börje Ekholm, President and CEO of Ericsson, says: \"Charlotte will be an integral part as we are entering the next chapter of Ericsson's strategy and in the continued evolution of the People agenda. She brings a strong track record from different organizations including different parts of Ericsson and I'm very much looking forward to having Charlotte join the Executive Team.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Commenting on the appointment, <span data-v-02ca9be7=\"\">Charlotte Levert</span> says: \"I am truly honored to take on this role and grateful for the trust. Working at Ericsson means we all get the chance to be part of shaping the future. I am looking forward to co-creating a future-proof organization and where Ericsson remains a great place to work.\"  </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In <span data-v-02ca9be7=\"\">October 2024</span> Ericsson announced that <span data-v-02ca9be7=\"\">MajBritt Arfert</span> would step down after having been with Ericsson for over 38 years and a member of the Company's Executive Team since the autumn of 2016. <span data-v-02ca9be7=\"\">MajBritt Arfert</span> will be available for Ericsson during the spring and leave Ericsson at the end of <span data-v-02ca9be7=\"\">May 2025</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">NOTES TO EDITORS:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">FOLLOW US:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Subscribe to Ericsson press releases <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=1079130181&amp;u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Fnewsroom%2Flatest-news%2Fpress-subscription&amp;a=here\" tabindex=\"0\">here</a><br data-v-02ca9be7=\"\"/>Subscribe to Ericsson blog posts <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2221444276&amp;u=https%3A%2F%2Fforyou.ericsson.com%2Fblog-subscription-center.html&amp;a=here\" tabindex=\"0\">here</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2037278625&amp;u=https%3A%2F%2Ftwitter.com%2Fericsson&amp;a=https%3A%2F%2Ftwitter.com%2Fericsson\" tabindex=\"0\">https://twitter.com/ericsson</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2291013006&amp;u=https%3A%2F%2Fwww.facebook.com%2Fericsson&amp;a=https%3A%2F%2Fwww.facebook.com%2Fericsson\" tabindex=\"0\">https://www.facebook.com/ericsson</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2256695802&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fericsson&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fericsson\" tabindex=\"0\">https://www.linkedin.com/company/ericsson</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">MORE INFORMATION AT:<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=3336389815&amp;u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Fnewsroom&amp;a=Ericsson+Newsroom\" tabindex=\"0\">Ericsson Newsroom</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:media.relations@ericsson.com\" tabindex=\"0\">media.relations@ericsson.com</a>  (+46 10 719 69 92)<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:investor.relations@ericsson.com\" tabindex=\"0\">investor.relations@ericsson.com</a>  (+46 10 719 00 00)</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">ABOUT ERICSSON:<br data-v-02ca9be7=\"\"/>Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2440795883&amp;u=http%3A%2F%2Fwww.ericsson.com%2F&amp;a=www.ericsson.com\" tabindex=\"0\">www.ericsson.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=3538047915&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=83647445&amp;u=https%3A%2F%2Fnews.cision.com%2Fericsson%2Fr%2Fericsson-appoints-charlotte-levert-as-chief-people-officer%2Cc4100082&amp;a=https%3A%2F%2Fnews.cision.com%2Fericsson%2Fr%2Fericsson-appoints-charlotte-levert-as-chief-people-officer%2Cc4100082\" tabindex=\"0\">https://news.cision.com/ericsson/r/ericsson-appoints-charlotte-levert-as-chief-people-officer,c4100082</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=4280032145&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F15448%2F4100082%2F3244109.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F15448%2F4100082%2F3244109.pdf\" tabindex=\"0\">https://mb.cision.com/Main/15448/4100082/3244109.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Ericsson appoints Charlotte Levert as Chief People Officer</span></p>\n</td></tr></tbody></table></span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/ericsson-appoints-charlotte-levert-as-chief-people-officer-302368573.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/ericsson-appoints-charlotte-levert-as-chief-people-officer-302368573.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Ericsson</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:05:45",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12275/ericsson-appoints-charlotte-levert-as-chief-people-officer",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "ASSA ABLOY: Quarterly Report Q4 2024",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nASSA ABLOY: Quarterly Report Q4 2024\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">ASSA ABLOY: Quarterly Report Q4 2024</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ --</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Margin target reached for year 2024</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth quarter</strong>         </p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Net sales increased by 7% to <span data-v-6f730619=\"\">SEK 39,575 M</span> (36,970), with organic growth of 0% (0) and acquired net growth of 6% (11). Exchange rates affected sales by 1% (1).           </li><li data-v-6f730619=\"\">Organic sales growth was strong in Global Technologies, good in Americas, stable in EMEIA, while organic sales declined in Entrance Systems and declined significantly in Asia Pacific.           </li><li data-v-6f730619=\"\">Eight acquisitions with combined annual sales of more than <span data-v-6f730619=\"\">SEK 1 bn</span> were completed in the quarter.           </li><li data-v-6f730619=\"\">Operating income<span data-v-6f730619=\"\">1</span> (EBITA) increased by 15% to a record <span data-v-6f730619=\"\">SEK 6,898 M</span> (6,008) with an operating margin of 17.4% (16.2).        </li><li data-v-6f730619=\"\">Operating income<span data-v-6f730619=\"\">1</span> (EBIT) increased by 14% and amounted to a record of <span data-v-6f730619=\"\">SEK 6,529 M</span> (5,722), with an operating margin of 16.5% (15.5).   </li><li data-v-6f730619=\"\">Net income<span data-v-6f730619=\"\">1 </span>amounted to a record <span data-v-6f730619=\"\">SEK 4,214 M</span> (3,969).        </li><li data-v-6f730619=\"\">Earnings per share<span data-v-6f730619=\"\">1</span> amounted to <span data-v-6f730619=\"\">SEK 3.81</span> (3.56).        </li><li data-v-6f730619=\"\">Record operating cash flow of <span data-v-6f730619=\"\">SEK 8,010 M</span> (7,315).         </li><li data-v-6f730619=\"\">The Board of Directors proposes a dividend of <span data-v-6f730619=\"\">SEK 5.90</span> (5.40) per share for 2024, to be distributed in two equal installments.</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sales and income</strong></p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth quarter</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">January-December</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2023</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2024</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Δ</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2023</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2024</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Δ</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sales, SEK M</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">36,970</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">39,575</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">140,716</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">150,162</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Of which:</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Organic growth</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">133</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–112 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">0 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,393</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–1,132 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–1%</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Acquisitions and divestments</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,572</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">2,215</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">10,651</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">11,326</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">8 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Exchange rate effects</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">349</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">502</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">5,879</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–748 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">0 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Operating income (EBIT)</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, SEK M</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">5,722</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">6,529</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">14 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">22,185</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">24,296</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">10 %</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Operating margin (EBITA)<span data-v-02ca9be7=\"\">1</span>, %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16.2 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">17.4 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16.5 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">17.1 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Operating margin (EBIT)</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">15.5 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">16.5 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">15.8 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">16.2 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Income before tax<span data-v-02ca9be7=\"\">1</span>, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4,879</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">5,684</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">19,654</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">20,914</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Net income<span data-v-02ca9be7=\"\">1</span>, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,969</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4,214</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">15,049</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">15,636</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Operating cash flow, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">7,315</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">8,010</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">10 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">25,232</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">23,052</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–9%</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Earnings per share</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, SEK</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">3.56</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">3.81</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">13.54</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">14.09</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">4 %</strong></span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1 </span>Excluding items affecting comparability. Please see the section \"Items affecting comparability\" in the report for further details about the financial effects in 2024. For information about items affecting comparability in 2023, please see the Year-end report 2023, available at assaabloy.com.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Comments by the President and CEO</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Margin target reached for year 2024</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">As we close 2024, I am proud to share that ASSA ABLOY showed resilience and agility in a mixed market environment, concluding the year with solid performance. For the full year, sales grew by 7%, reflecting strong contribution from acquisitions of 8%, and a small organic sales decline of 1%. Our operating margin expanded to 16.2%, within the target range of 16-17%.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In the fourth quarter of 2024, organic sales were stable, with net positive contribution from acquisitions of 6% and currency effects of 1%. Global Technologies delivered strong organic growth of 5% with strong performance in most business areas and with Physical Access Control having comparable figures at normalized levels for the full quarter. Americas delivered good organic growth of 2%, with strong growth in the North America Non-Residential segment and in <span data-v-02ca9be7=\"\">Latin America</span>. Organic sales were stable in EMEIA with commercial segments compensating for continued weak residential demand. Similarly, weak residential markets and weak demand for loading docks resulted in an organic sales decline of 2% in Entrance Systems. <span data-v-02ca9be7=\"\">Asia Pacific's</span> organic sales declined significantly by 11%, mainly due to very weak demand in <span data-v-02ca9be7=\"\">China</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The operating profit for the quarter increased by 14% to a record <span data-v-02ca9be7=\"\">SEK 6,529 M</span> with a corresponding margin of 16.5% (15.5). The operating leverage was very strong at 120 bps, driven by continued price/cost tailwind and strong operational execution, overcompensating for dilution from acquisitions. The operating cash flow increased by 10% in the quarter to a record <span data-v-02ca9be7=\"\">SEK 8,010 M</span> with a cash conversion of 141% (150).</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Focus on accelerating our sales growth</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Accelerating organic growth remains a key priority going forward. An important part of our strategy is upgrading the installed base with innovative digital and electromechanical products and solutions. We invest 4% of annual sales in R&amp;D which allows us to strengthen our offering and drive the transition forward. Electromechanical products and solutions are the most important growth driver in our portfolio, with currency adjusted growth of 8% in 2024 and an annual growth rate of 9% in the last ten years in our regional divisions. Through upgrades we can support customers with enhanced security and convenience, but also grow recurring revenue streams. Recurring revenue continues to be a key driver for growth with subscription-based models, service agreements, and digital solutions like remote monitoring and mobile access. In 2024, sales of our subscription-based solutions grew by 18%. Our <span data-v-02ca9be7=\"\">decentralized</span> organization and region-specific product development provide further opportunities in the emerging markets, that only represent 13% of our sales. In 2024, our currency adjusted sales in emerging markets excluding <span data-v-02ca9be7=\"\">China</span> grew by 10%.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">A record 26 acquisitions were completed in 2024, adding annualized sales close to <span data-v-02ca9be7=\"\">SEK 8 bn</span>. In the fourth quarter, we completed eight acquisitions. Acquisitions remain a key driver for growth and the pipeline remains strong.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">By leveraging our market-leading products and solutions with our local knowledge and global presence, we are confident in our ability to drive continued value for our customers, employees and shareholders. Finally, I would like to thank my colleagues for their outstanding contributions during the year and all our stakeholders for your trust.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Stockholm</span>, <span data-v-02ca9be7=\"\">February 5, 2025</span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Nico Delvaux</span><br data-v-02ca9be7=\"\"/>President and CEO</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Further information can be obtained from:<br data-v-43363f62=\"\"/></strong><span data-v-02ca9be7=\"\">Nico Delvaux</span>,<br data-v-02ca9be7=\"\"/>President and CEO, tel. no: +46 8 506 485 82<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Erik Pieder,<br data-v-02ca9be7=\"\"/>Executive Vice President and CFO, tel.no: +46 8 506 485 72<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Björn Tibell,<br data-v-02ca9be7=\"\"/>Head of Investor Relations, tel. no: +46 70 275 67 68<br data-v-02ca9be7=\"\"/>e-mail: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:bjorn.tibell@assaabloy.com\" tabindex=\"0\">bjorn.tibell@assaabloy.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">ASSA ABLOY is holding a <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">telephone and web conference at 09.00 on <span data-v-43363f62=\"\">February 5, 2025</span></strong> which can be followed online at <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=3396980910&amp;u=https%3A%2F%2Fwww.assaabloy.com%2Fse%2Fen&amp;a=assaabloy.com%2Finvestors\" tabindex=\"0\">assaabloy.com/investors</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">It is possible to submit questions by telephone on: 08–505 100 31, +44 207 107 0613 or +1 631 570 5613</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">This information is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on <span data-v-370fea16=\"\">February 5, 2025</span>.</em></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=1220740761&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=664758152&amp;u=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fr%2Fquarterly-report-q4-2024%2Cc4100644&amp;a=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fr%2Fquarterly-report-q4-2024%2Cc4100644\" tabindex=\"0\">https://news.cision.com/assa-abloy/r/quarterly-report-q4-2024,c4100644</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=379784&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F7333%2F4100644%2F3246382.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F7333%2F4100644%2F3246382.pdf\" tabindex=\"0\">https://mb.cision.com/Main/7333/4100644/3246382.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">The full report (PDF)</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=3484264407&amp;u=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fi%2Fassa-abloy-logo-door%2Cc3374416&amp;a=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fi%2Fassa-abloy-logo-door%2Cc3374416\" tabindex=\"0\">https://news.cision.com/assa-abloy/i/assa-abloy-logo-door,c3374416</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">ASSA ABLOY logo door</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/assa-abloy-quarterly-report-q4-2024-302368577.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/assa-abloy-quarterly-report-q4-2024-302368577.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  ASSA ABLOY</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:05:45",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12263/assa-abloy-quarterly-report-q4-2024",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Harmony Gold Reports Five Deaths at Two Separate South African Mines",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Ian Walker </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Harmony Gold Mining said that five people died in two separate incidents in South Africa on Tuesday morning and that the causes of the accidents are currently under investigation. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The South African gold miner said Wednesday that two employees died following a mining incident at a development end at Doornkop Mine, in Soweto, Gauteng province. All blasting operations have been temporarily suspended at the mine, it said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Separately a further three employees died following rock falls at Harmony's Joel Mine, near Theunissen in the Free State Province. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The company said that the relevant authorities have been kept fully informed of the incidents, adding that investigations into the incidents will be led by the Department of Mineral Resources and Energy, supported by labour representatives and mine management at each operation. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Ian Walker at ian.walker@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:35 ET (07:35 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:50:43",
            "link": "https://www.morningstar.com/news/dow-jones/202502052000/harmony-gold-reports-five-deaths-at-two-separate-south-african-mines",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "GSK Expects Further Profit Growth After Beating Market Views",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Helena Smolak </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  GSK expects its sales and profit to grow in the new year after cancer treatments lifted sales and profit ahead of analysts' expectations in the fourth quarter despite lower vaccines sales on weak demand in the U.S. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The British pharmaceutical giant said Wednesday that for 2025 it expects sales to grow 3% to 5%. It also targets core operating profit and core earnings per share to grow between 6% and 8%. Targets are at constant exchange rates. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  This compares with 2024 sales growth of 7%, core operating profit growth of 11% and core earnings per share growth of 10%. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Its fourth-quarter sales rose 4% at constant currencies to 8.12 billion pounds ($10.13 billion), above the 7.83 billion pounds that analysts had expected, according to a consensus polled by Visible Alpha. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Core operating profit, closely watched by analysts and investors, fell 10% at constant currencies to 1.43 billion pounds on lower-than-anticipated vaccine sales. Analysts had expected 1.385 billion pounds. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Its core earnings per share fell 10% at constant currencies to 23.2 pounds, above analysts' expectations of 20.6 pounds. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Helena Smolak at helena.smolak@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:43 ET (07:43 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:50:43",
            "link": "https://www.morningstar.com/news/dow-jones/202502052063/gsk-expects-further-profit-growth-after-beating-market-views",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Novo Nordisk's Wegovy Drug Sales Miss Expectations",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Dominic Chopping </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The Danish pharmaceutical giant said sales of Wegovy surged to 19.87 billion Danish kroner ($2.76 billion), against a Visible Alpha consensus estimate of 20.04 billion kroner. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Sales of diabetes drug Ozempic rose 12% on year to 33.85 billion kroner at constant exchange rates, with a Visible Alpha consensus estimate looking for 33.34 billion kroner. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The sales performance comes after Eli Lilly, the company's biggest competitor in the booming weight-loss market, presented a disappointing fourth-quarter sales forecast for its Zepbound and Mounjaro medications. The U.S. company said it had expected faster market growth of the drugs, but wholesalers hadn't boosted their stockpiles at the end of the year as it had expected them to. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Dominic Chopping at dominic.chopping@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:19 ET (07:19 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:30:47",
            "link": "https://www.morningstar.com/news/dow-jones/202502051835/novo-nordisks-wegovy-drug-sales-miss-expectations",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Sobi publishes Q4 2024 report: A solid ending to a strong year",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nSobi publishes Q4 2024 report: A solid ending to a strong year\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Sobi publishes Q4 2024 report: A solid ending to a strong year</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Swedish Orphan Biovitrum AB (publ) (Sobi<span data-v-43363f62=\"\">®</span>) today announced its report for the fourth quarter 2024.</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth Quarter 2024</strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)<span data-v-6f730619=\"\">1</span>, to <span data-v-6f730619=\"\">SEK 7,436 M</span> (6,844)</li><li data-v-6f730619=\"\">Haematology revenue increased 22 per cent at CER to <span data-v-6f730619=\"\">SEK 4,487 M</span> (3,640), mainly driven by strong sales of Doptelet<span data-v-6f730619=\"\">® </span>of <span data-v-6f730619=\"\">SEK 1,147 M</span> (727), Vonjo<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 416 M</span> (322), Aspaveli<span data-v-6f730619=\"\">®</span>/Empaveli<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 269 M</span> (186) and launch sales of Altuvoct<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 302 M</span> (2)</li><li data-v-6f730619=\"\">Immunology revenue decreased 12 per cent at CER to <span data-v-6f730619=\"\">SEK 2,564 M</span> (2,905), explained by low Synagis<span data-v-6f730619=\"\">®</span> sales of <span data-v-6f730619=\"\">68 M</span> (897), partially offset by Beyfortus<span data-v-6f730619=\"\">®</span> royalty of <span data-v-6f730619=\"\">SEK 1,207 M</span> (890) and sales of Kineret<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 777 M</span> (621)</li><li data-v-6f730619=\"\">Revenue from the strategic portfolio<span data-v-6f730619=\"\">1*</span> grew by 50 per cent at CER to <span data-v-6f730619=\"\">SEK 4,099 M</span> (2,722)</li><li data-v-6f730619=\"\">The adjusted EBITA margin<span data-v-6f730619=\"\">1,2</span> was 34 per <span data-v-6f730619=\"\">cent (38)</span>, excluding items affecting comparability (IAC)<span data-v-6f730619=\"\">2</span>. EBITA was <span data-v-6f730619=\"\">SEK 2,572 M</span> (2,502), corresponding to a margin of 35 per <span data-v-6f730619=\"\">cent (37)</span>. EBIT was <span data-v-6f730619=\"\">SEK 1,662 M</span> (1,610)</li><li data-v-6f730619=\"\">Earnings per share (EPS) before dilution was <span data-v-6f730619=\"\">SEK 4.07</span> (3.02). Adjusted EPS before dilution<span data-v-6f730619=\"\">1</span> was <span data-v-6f730619=\"\">SEK 4.03</span> (3.21). Cash flow from operating activities was <span data-v-6f730619=\"\">SEK 1,797 M</span> (1,073)</li><li data-v-6f730619=\"\"><span data-v-6f730619=\"\">David Meek</span> was elected as a new member, and as Chair of the Board of Directors</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Full Year 2024 </strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Total revenue increased 18 per cent, 19 per cent at CER to <span data-v-6f730619=\"\">SEK 26,027 M</span> (22,123). Haematology grew 24 per cent at CER and Immunology grew 11 per cent at CER</li><li data-v-6f730619=\"\">The adjusted EBITA margin<span data-v-6f730619=\"\">1,2</span> was 36 per <span data-v-6f730619=\"\">cent (34)</span>, excluding IAC<span data-v-6f730619=\"\">2</span></li><li data-v-6f730619=\"\">The board of directors proposes that no dividend is paid for the 2024 financial year</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Outlook 2025 </strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Revenue is anticipated to grow by a high single-digit percentage at CER</li><li data-v-6f730619=\"\">The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue</li></ul><span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1.</span> Alternative Performance Measures (APMs).</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">2.</span> Items affecting comparability (IAC).</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant<span data-v-02ca9be7=\"\">®</span>, Vonjo and Zynlonta<span data-v-02ca9be7=\"\">®</span>, and royalty on Sanofi's sales of Altuviiio<span data-v-02ca9be7=\"\">®</span> and Beyfortus.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Investors, analysts, and the media are invited to a conference call on the same day at <span data-v-02ca9be7=\"\">14:30 CET</span>, <span data-v-02ca9be7=\"\">13:30 GMT</span>, and <span data-v-02ca9be7=\"\">08:30 EST</span>. The call will include a presentation of the results and a Q&amp;A session.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The presentation can be followed live <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2865459923&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3DJ7Y4u1Ji&amp;a=here\" tabindex=\"0\">here</a> or afterwards on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a>. The slides will be made available on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a> before the conference call.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">To participate in the conference call, please use the following dial-in details:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Sweden</span>: +46 8 5051 0031<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">United Kingdom</span>: +44 207 107 06 13<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">United States</span>: +1 631 570 56 13</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For other countries, please find the details <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=3357748000&amp;u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fservices3.choruscall.ch%252FNUMBERS%252FAttended_Dial_In_Numbers.pdf%26data%3D05%257C02%257Cssantamaria%2540choruscall.com%257Cc46caccf82394f1c8ffd08dc369c2a22%257Cb33d8fee5ac94ed69e4d5ad041ecfd21%257C0%257C0%257C638445292073810488%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C0%257C%257C%257C%26sdata%3DTVLldmPZmSnOWKSwGGe2CdG1TlgV7dEF2ypcHkkECNE%253D%26reserved%3D0&amp;a=here\" tabindex=\"0\">here</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sobi</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Sobi<span data-v-02ca9be7=\"\">®</span> is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across <span data-v-02ca9be7=\"\">Europe</span>, <span data-v-02ca9be7=\"\">North America</span>, the <span data-v-02ca9be7=\"\">Middle East</span>, <span data-v-02ca9be7=\"\">Asia</span> and <span data-v-02ca9be7=\"\">Australia</span>. In 2024, revenue amounted to <span data-v-02ca9be7=\"\">SEK 26 billion</span>. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a> and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2560329666&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsobi%2F&amp;a=LinkedIn\" tabindex=\"0\">LinkedIn</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Contacts</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For details on how to contact the Sobi Investor Relations Team, please click <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2060125289&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fir-contacts&amp;a=here\" tabindex=\"0\">here</a>. For Sobi Media contacts, click <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=693482582&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fmedia&amp;a=here\" tabindex=\"0\">here</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on <span data-v-02ca9be7=\"\">05 February 2025</span> at <span data-v-02ca9be7=\"\">8:00 CET</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Gerard Tobin</span><br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">Head of Investor Relations</span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2303580505&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=1025089076&amp;u=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year%2Cc4100452&amp;a=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year%2Cc4100452\" tabindex=\"0\">https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year,c4100452</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=1204790555&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4100452%2F3245896.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4100452%2F3245896.pdf\" tabindex=\"0\">https://mb.cision.com/Main/14266/4100452/3245896.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Q4 and FY 2024 report. A solid ending to a strong year</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year-302368539.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year-302368539.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Swedish Orphan Biovitrum AB</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 15:30:46",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12264/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "HUSQVARNA GROUP: YEAR-END REPORT JANUARY - DECEMBER 2024",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nHUSQVARNA GROUP: YEAR-END REPORT JANUARY - DECEMBER 2024\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">HUSQVARNA GROUP: YEAR-END REPORT JANUARY - DECEMBER 2024</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- Strong cash flow during a challenging year</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth quarter 2024</strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Net sales decreased by 2% to SEK 8,464m (8,605). Changes in exchange rates contributed with 1%. Sales declined organically by 3%.</li><li data-v-6f730619=\"\">Operating income amounted to SEK -1,285m (-983) and the operating margin was -15.2% (-11.4).</li><li data-v-6f730619=\"\">Excluding items affecting comparability, the operating income amounted to SEK -694m (-168) and the operating margin was -8.2% (-1.9).</li><li data-v-6f730619=\"\">Items affecting comparability amounted to SEK -591m (-815), and was related to the Group's cost savings initiatives, announced in <span data-v-6f730619=\"\">October 2024</span> and related to costs following the reclassification of the <span data-v-6f730619=\"\">Orangeburg</span> manufacturing facility in <span data-v-6f730619=\"\">North America</span> to assets held for sale.</li><li data-v-6f730619=\"\">Earnings per share after dilution amounted to SEK -1.95 (-1.77) and earnings per share excluding items affecting comparability and after dilution amounted to SEK -1.15 (-0.67).</li><li data-v-6f730619=\"\">Cash flow from operations and investments amounted to SEK -925m (-743). Direct operating cash flow increased to <span data-v-6f730619=\"\">SEK 582m</span> (523).</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">January – <span data-v-43363f62=\"\">December 2024</span></strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Net sales decreased by 9% to SEK 48,352m (53,261). Changes in exchange rates had a neutral effect.</li><li data-v-6f730619=\"\">Planned exits of low-margin petrol-powered business impacted with -2%. Sales declined organically by 7%.</li><li data-v-6f730619=\"\">Operating income was SEK 2,597m (3,880) and the operating margin was 5.4% (7.3).</li><li data-v-6f730619=\"\">Excluding items affecting comparability, the operating income amounted to SEK 3,195m (4,970) and the operating margin was 6.6% (9.3).</li><li data-v-6f730619=\"\">Earnings per share after dilution amounted to <span data-v-6f730619=\"\">SEK 2.31</span> (3.81) and earnings per share excluding items affecting comparability and after dilution amounted to SEK 3.12 (5.28).</li><li data-v-6f730619=\"\">Cash flow from operations and investments was SEK 4,372m (4,414). Direct operating cash flow increased to <span data-v-6f730619=\"\">SEK 6,905m</span> (6,541), driven by reduced inventories.</li><li data-v-6f730619=\"\">The CO<span data-v-6f730619=\"\">2</span> emissions across the value chain have been reduced by -56% (-44) compared to the 2015 base line, see page 8.</li><li data-v-6f730619=\"\">The Board of Directors will propose a dividend for 2024 of SEK 1.00 per share (3.00) to the Annual General Meeting.</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Strong cash flow during a challenging year</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\"In 2024, we accelerated our focus on executing the strategy and adapting the organization to drive efficiency and continued transformation. This enabled us to achieve significant cost savings, deliver strong cash flow, and implement a comprehensive product launch program for the 2025 season.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Challenging market conditions in the fourth quarter</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The year's challenging market situation continued into the fourth quarter, with subsequently lower consumer demand. The Group's sales declined organically by 3% and the operating income, excluding items affecting comparability, amounted to SEK -694m (-168) for the fourth quarter.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In the Husqvarna Forest &amp; Garden Division, organic growth was unchanged for the quarter, with growth in handheld and wheeled products, as well as in parts and accessories. Sales in the Gardena Division decreased, with growth for hand tools, while sales of watering products declined. In the Husqvarna Construction Division, sales declined in <span data-v-02ca9be7=\"\">North America</span> due to a continuation of the challenging market situation, however, our sales increased in <span data-v-02ca9be7=\"\">Europe</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Strong cash flow and reduced net debt</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For the full year 2024, operating income, excluding items affecting comparability, amounted to SEK 3.2bn (5.0). The decrease was due to lower sales volumes with higher promotional activities and a negative product mix. This was partly offset by good results from savings programs, which generated <span data-v-02ca9be7=\"\">SEK 735m</span>. Direct operating cash flow increased to <span data-v-02ca9be7=\"\">SEK 6.9bn</span> (6.5), driven by substantial inventory reductions. We have reduced net debt by <span data-v-02ca9be7=\"\">SEK 1.2bn</span> compared to last year. The Board will propose to the Annual General Meeting a dividend of <span data-v-02ca9be7=\"\">SEK 1.00</span> (3.00) for the year, in line with our dividend policy, representing 32% of earnings per share excluding items affecting comparability, or 43% of earnings per share.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Improving results in <span data-v-43363f62=\"\">North America</span></strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In recent years, the Husqvarna Forest &amp; Garden Division has taken decisive actions to improve results in <span data-v-02ca9be7=\"\">North America</span>. Low-margin business has been discontinued and the production structure has been consolidated. We are now entering the next step where we divest our manufacturing facility in <span data-v-02ca9be7=\"\">Orangeburg, SC</span>, to Flex Ltd. In parallel, we have entered a long-term supplier agreement with Flex, to ensure continued production of the division's wheeled products and assembly of handheld products in the US. This is a partnership that will build profitability, improve capital efficiency, enhance production flexibility and strengthen our competitiveness in <span data-v-02ca9be7=\"\">North America</span>. Related cost savings are expected to amount to <span data-v-02ca9be7=\"\">SEK 350m</span> by 2030 (see page 9).</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Our strategic transformation continues</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Our long-term transformation is about delivering value to customers, shareholders and employees through growth in the focus areas; robotic mowers, battery-powered products, watering and solutions for the professional market. Since 2021 we measure our progress through operational ambitions, including share of electrification, number of connected devices, and sales of robotic mowers. During the year, the share of electrified products reached 44% (42) of our sales of motorized products. Connected devices grew to 4.9 million (4.5). For robotic mowers, net sales amounted to SEK 7.2bn (8.1). We strengthened our position and grew in the professional robotics market. However, sales in the residential segment declined due to increased competition in the low-value segments, as well as restrained consumer spending, particularly for the high value segments. For the 2025 season, we have significantly expanded our range with new boundary wire-free robotic mowers.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">As the current strategic period for the Group approaches its end, our focus remains firm – we are continuing to prioritize areas with profitable growth potential, and we will present an update of our strategy at a Capital Markets Day in the fourth quarter of 2025.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">We deliver on our sustainability targets</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Our ambition to electrify the product range is the main enabler to consistently reduce our carbon footprint. To date, we have reduced CO<span data-v-02ca9be7=\"\">2</span> emissions (Scope 1, 2 and 3) by -56% compared with the base year of 2015. With that, we have exceeded our target of a -35% reduction by 2025. Work to reduce CO<span data-v-02ca9be7=\"\">2</span> emissions is continuing and includes exploring alternative fuels for some of our products.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">I would like to express my gratitude to all colleagues and business partners for their efforts and support during the year. Together, we will continue to focus on opportunities in the market, strengthen our position and aim to increase our profitability. Our cost-saving efforts are successful, and we are well prepared for the 2025 season, with a strong product range and many exciting launches for our customers.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><span data-v-370fea16=\"\">Pavel Hajman</span>, CEO</em> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Webcast presentation and telephone conference</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">A webcast presentation of the Q4 report hosted by Pavel Hajman, CEO and <span data-v-02ca9be7=\"\">Terry Burke</span>, CFO will be held at <span data-v-02ca9be7=\"\">10:00 CET</span> on <span data-v-02ca9be7=\"\">February 5, 2025</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">To view the presentation, please use the link: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=2210094975&amp;u=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fhusqvarnagroup.creo.se%252F4f888317-fb0e-4ca4-9abd-4d677a0dda92%26data%3D05%257C02%257CJenny.Huselius%2540husqvarnagroup.com%257C4e0a8e7e2a504df2b25b08dd1de7c538%257C2a1c169e715a412bb52605da3f8412fa%257C0%257C0%257C638699603495650749%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DPscTsNFXM3XBRpNjr2QhNrpQ4iAIz9Q71La5UAu7D5s%253D%26reserved%3D0&amp;a=https%3A%2F%2Fhusqvarnagroup.creo.se%2F4f888317-fb0e-4ca4-9abd-4d677a0dda92\" tabindex=\"0\">https://husqvarnagroup.creo.se/4f888317-fb0e-4ca4-9abd-4d677a0dda92</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The dial-in to the telephone conference (in order to ask questions): +46 (0) 8 505 100 31 (<span data-v-02ca9be7=\"\">Sweden</span>) or +44 207 107 06 13 (UK) </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Dates for Financial Reports 2025</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">April 24           Interim report for January-<span data-v-02ca9be7=\"\">March 2025</span><br data-v-02ca9be7=\"\"/>April 29           Annual General Meeting 2025<br data-v-02ca9be7=\"\"/>July 18            Interim report for January-<span data-v-02ca9be7=\"\">June 2025</span><br data-v-02ca9be7=\"\"/>October 21      Interim report for January-<span data-v-02ca9be7=\"\">September 2025</span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Contacts</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Terry Burke, CFO and Executive Vice President, Finance, IR &amp; Communication<br data-v-02ca9be7=\"\"/>+46 8 738 90 00<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">Johan Andersson</span>, Vice President, Investor Relations<br data-v-02ca9be7=\"\"/>+46 702 100 451<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Husqvarna AB (publ), P.O. Box 7454, SE-103 92 Stockholm<br data-v-02ca9be7=\"\"/>Regeringsgatan 28, +46 8 738 90 00, <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=2382916971&amp;u=https%3A%2F%2Fwww.husqvarnagroup.com%2F&amp;a=www.husqvarnagroup.com\" tabindex=\"0\">www.husqvarnagroup.com</a> <br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Reg. Nr: 556000-5331<br data-v-02ca9be7=\"\"/>NASDAQ OMX Stockholm: HUSQ A, HUSQ B</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">This report contains insider information that Husqvarna AB is required to disclose under the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the contact person set out above, at 07.00 CET on <span data-v-370fea16=\"\">February 5, 2025</span></em> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Factors affecting forward-looking statements</strong></em><br data-v-02ca9be7=\"\"/><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">This report contains forward-looking statements in the sense referred to in the American Private Securities Litigation Reform Act of 1995. Such statements comprise, among other things, financial goals, goals of future business and financial plans. These statements are based on present expectations and are subject to risks and uncertainties that may give rise to major deviations in the result due to several aspects. These aspects include, among other things: consumer demand and market conditions in the geographical areas and lines of business in which Husqvarna operates, the effects of currency fluctuations, downward pressure on prices due to competition, a material reduction in sales by important distributors, success in developing new products and in marketing, outcome of product responsibility litigation, progress in terms of reaching the goals set for productivity and efficient use of capital, successful identification of growth opportunities and acquisition objects, integration of these into the existing business and successful achievement of goals for making the supply chain more efficient.</em></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=3622313514&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=3688614696&amp;u=https%3A%2F%2Fnews.cision.com%2Fhusqvarna-group%2Fr%2Fyear-end-report-january---december-2024%2Cc4100673&amp;a=https%3A%2F%2Fnews.cision.com%2Fhusqvarna-group%2Fr%2Fyear-end-report-january---december-2024%2Cc4100673\" tabindex=\"0\">https://news.cision.com/husqvarna-group/r/year-end-report-january---december-2024,c4100673</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=4002245176&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F996%2F4100673%2F3246444.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F996%2F4100673%2F3246444.pdf\" tabindex=\"0\">https://mb.cision.com/Main/996/4100673/3246444.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Interim report Q4 2024 Husqvarna Group (PDF)</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355844-1&amp;h=2609737335&amp;u=https%3A%2F%2Fnews.cision.com%2Fhusqvarna-group%2Fi%2Fpavel-hajman--ceo%2Cc3374432&amp;a=https%3A%2F%2Fnews.cision.com%2Fhusqvarna-group%2Fi%2Fpavel-hajman--ceo%2Cc3374432\" tabindex=\"0\">https://news.cision.com/husqvarna-group/i/pavel-hajman--ceo,c3374432</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Pavel Hajman, CEO</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12234&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/husqvarna-group-year-end-report-january---december-2024-302368523.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/husqvarna-group-year-end-report-january---december-2024-302368523.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Husqvarna Group</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 15:20:44",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12234/husqvarna-group-year-end-report-january-december-2024",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations — Update",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Adria Calatayud </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Banco Santander said it plans to buy back 10 billion euros ($10.38 billion) of its own stock after it reported fourth-quarter results that exceeded expectations both at the top and bottom lines. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Spain's biggest bank by assets became the latest in Europe to outline plans for bumper returns to shareholders. Lenders took steps to clean up their balance sheets and restore profitability amid high interest rates in recent years and have continued to hand money back to shareholders even as central banks moved to lower rates. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Santander said Wednesday that it expects to return 10 billion euros to shareholders through stock repurchases from its earnings this year and next on top of its dividend. The bank said it plans to start with a new program of about 1.59 billion euros on Thursday for which it already obtained regulatory authorization. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Its plans came hot on the heels of buyback announcements on Tuesday from UBS Group, Intesa Sanpaolo and BNP Paribas. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Santander said it was confident it would be able to boost profitability again in 2025, raising a key profitability target despite projecting broadly stable revenue for the year. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Net profit for the fourth quarter was 3.265 billion euros, up 11% on year, Santander said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Total income for the quarter rose 10% to 16.03 billion euros, mainly driven by higher net fee income. Net interest income--the difference between what a bank earns on loans and what it pays clients for deposits--came to 11.99 billion euros, up 6.8% on the prior quarter. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Analysts had expected Santander to post a net profit of 2.95 billion euros on revenue of 15.39 billion euros, according to consensus estimates provided by Visible Alpha. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The bank attributed the profit rise to increases at its main income streams that offset higher costs and a hit from a U.K. provision related to cover potential costs from a court ruling on the disclosure of dealer commissions on car loans. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  For 2025, Santander expects revenue of about 62 billion euros, mid-high single digit growth in net fee income, lower costs and a return on tangible equity--a key profitability metric for banks--of more than 17%. It had previously targeted a 2025 return on tangible equity of 15% to 17%. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  \"Our track record shows that in a challenging market we outperform peers and in 2025 we expect to grow our bottom line and profitability--with revenue stable and costs falling,\" Santander's Executive Chair Ana Botin said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The bank's full-year revenue climbed 7.9% to 61.88 billion euros in 2024 and its return on tangible equity for the year stood at 16.3%, up from 15.1% a year before. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Adria Calatayud at adria.calatayud@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:10 ET (07:10 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:20:43",
            "link": "https://www.morningstar.com/news/dow-jones/202502051636/santander-plans-104-billion-in-buybacks-after-results-beat-expectations-update",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        }
    ]
}